



Schweizerische Pädiatrische Onkologie Gruppe  
Groupe d'Oncologie Pédiatrique Suisse  
Gruppo d'Oncologia Pediatrica Svizzera  
Swiss Paediatric Oncology Group

## ALCL-Relapse

Anaplastic large cell lymphoma (ALCL) is a rare type of lymphoma in children and adolescence. ALCL are highly sensitive to chemotherapy with complete remission rates ranging from 65-90%. However, for the 25-40% of patients developing a relapse of the disease, there was no clear guide to the most appropriate treatment at the time. The heterogeneity of relapsed ALCL called for a risk group adapted therapy intensity.

The ALCL-relapse study tested newly introduced criteria to stratify patients in three groups depending on specific characteristics of their disease. The treatment intensity in each group was adapted to the risk of the patient having a second relapse. The main objective of the study was to improve treatment and outcome of all children and adolescents with early progression or relapse. In addition, bone marrow and blood samples have been collected and analysed throughout the study to gather more knowledge about ALCL relapse and identify new treatment approaches for future patients. The study is terminated. The Universitäts-Kinderklinik Giessen in Germany is responsible for the international implementation of the study (sponsor). In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for the conduct of the study (sponsor representative).

### **Contact details for the sponsor representative in Switzerland:**

Partner Relations  
SPOG Coordinating Center  
Effingerstrasse 33  
3008 Bern  
Phone: +41 31 389 91 89